Abstract:Q, Role of HIF-1 (cid:1) in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 297: L631–L640, 2009. doi:10.1152/ajplung.90415.2008.—Angio-tensin-converting enzyme (ACE) enhances the proliferation and migration of pulmonary artery smooth muscle cells (PASMCs), which contribute to the pathogenesis of hypoxic pulmonary hypertension (HPH). Previous reports have demonstrated that hypoxia upregulates ACE expression, but the underlying mechanism is unknown. Here, we found that ACE is persistently upregulated in PASMCs on the transcriptional level during hypoxia. Hypoxia-inducible factor 1 (cid:1) (HIF-1 (cid:1) ), a key transcription factor activated during hypoxia, was able to upregulate ACE protein expression under normoxia, whereas knockdown of HIF-1 (cid:1) expression in PASMCs inhibited hypoxia-induced ACE upregulation. Furthermore, HIF-1 (cid:1) can bind and transactivate the ACE promoter directly. Therefore, we report that ACE is a novel target of HIF-1 (cid:1) . Recently, a homolog of ACE, ACE2, was reported to counterbalance the function of ACE. In contrast to ACE, we found that ACE2 mRNA and protein levels increased during the early stages of hypoxia and decreased to near-baseline levels at the later stages after HIF-1 (cid:1) accumulation. Thus HIF-1 (cid:1) inhibited ACE2 expression, and the accumulated ANG II catalyzed by ACE is a key mediator in the downregulation of ACE2 by HIF-1 (cid:1) . Moreover, a reduction of ACE2 expression in PASMCs by RNA interference was accompanied by signiﬁcantly enhanced proliferation and migration during hypoxia. We conclude that ACE is directly regulated by HIF-1 (cid:1) , whereas ACE2 is regulated in a bidirectional way during hypoxia and may play a protective role during the development of HPH. In sum, these ﬁndings contribute to the understanding of the pathogenesis of HPH. Effectene transfection reagent (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The transfection mixture was removed 12 h after transfection, and fresh medium was added. The transfection efﬁciency in the cells was monitored by the cotransfec-tion of 50 ng of pEGFP plasmid (Clontech, Palo Alto, CA), which expressed green ﬂuorescence protein (GFP). pEF-BOS plasmid was transfected as a negative control. Transfected cells were analyzed 36 h after transfection. levels via an HIF-1 (cid:1) -independent path- way. II activates the ANG II type 1 (AT 1 ) receptor on hPASMCs to reduce ACE2 protein synthesis. ACE inhibitor (ACEI) and AT 1 receptor antagonists can upregulate ACE2 during hypoxia by blocking formation and action of ANG II, respectively.

AMP-activated Protein Kinase Phosphorylation of Angiotensin-Converting Enzyme 2 in Endothelium Mitigates Pulmonary Hypertension.

Overexpression of ACE2 Prevents Hypoxia-Induced Pulmonary Hypertension in Rats by Inhibiting Proliferation and Immigration of PASMCs.

MDM2-Mediated Ubiquitination of Angiotensin-Converting Enzyme 2 Contributes to the Development of Pulmonary Arterial Hypertension

Endothelial Scaffolding Protein ENH (Enigma Homolog Protein) Promotes PHLPP2 (Pleckstrin Homology Domain and Leucine-Rich Repeat Protein Phosphatase 2)-Mediated Dephosphorylation of AKT1 and eNOS (Endothelial NO Synthase) Promoting Vascular Remodeling.

Angiotensin Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis and Diastolic Dysfunction

A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension

The role and mechanism of AMPK in pulmonary hypertension

Activation AMPK in Hypothalamic Paraventricular Nucleus Improves Renovascular Hypertension Through ERK1/2-NF-κB Pathway

Prevention of Angiotensin II-induced Hypertension and Cardiac Remodeling by Recombinant Human Angiotensin-Converting Enzyme 2 in Mice

1039 ACE2 DEFICIENCY FACILIATES ANGIOTENSIN II-MEDIATED VASCULAR PEROXYNITRITE PRODUCTION WITH ACTIVATION OF THE AKT/ENOS SIGNALING

Progress of Pathophysiological Mechanism of Angiotensin-Converting Enzyme 2 in Treating Pulmonary Arterial Hypertension

AMPK and Pulmonary Hypertension: Crossroads Between Vasoconstriction and Vascular Remodeling

Gut Pathology and Its Rescue by ACE2 (Angiotensin-Converting Enzyme 2) in Hypoxia-Induced Pulmonary Hypertension

Regulatory effect of AMP-activated protein kinase on pulmonary hypertension induced by chronic hypoxia in rats: in vivo and in vitro studies

Inactivation of Malic Enzyme 1 in Endothelial Cells Alleviates Pulmonary Hypertension

AMPK Attenuation of β-Adrenergic Receptor-Induced Cardiac Injury via Phosphorylation of β-Arrestin-1-ser330

ACE2 overexpression in corticotropin-releasing-hormone cells offers protection against pulmonary hypertension

Aldehyde Dehydrogenase 2 (ALDH2) Elicits Protection against Pulmonary Hypertension via Inhibition of ERK1/2-Mediated Autophagy

Inhibition of the AMP-activated Protein Kinase-Α2 Accentuates Agonist-Induced Vascular Smooth Muscle Contraction and High Blood Pressure in Mice.

Role of HIF-1 (cid:1) in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells

Amp Activated Protein Kinase-Alpha 2 Regulates Expression Of Estrogen-Related Receptor-Alpha, A Metabolic Transcription Factor Related To Heart Failure Development